The use of Topical Brimonidine in Dermatology | ||||
| Minia Journal of Medical Research | ||||
| Article 40, Volume 30, Issue 3, July 2019, Page 199-202 PDF (180.88 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2022.221927 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Moetaz B. El-Domyati; Walid M. Abd El-Naeim; Samah S. Abdel hameed | ||||
| Department of Dermatology, El-Minia Faculty of Medicine | ||||
| Abstract | ||||
| Introduction: Brimonidine tartrate is a lipid soluble alpha 2 adrenergic highly selective receptor agonist with potent vasoconstrictor activity that had been approved for management of open angle glaucoma, it is also currently indicated for the topical treatment of persistent (nontransient) facial erythema. Aim of the Work: The aim of the present study is to evaluate the use and effectiveness of topical brimonidine (alpha 2 adrenergic receptor agonist) clinically and histologically, for the management of facial erythema. Patients and Methods: The study was conducted on 20 patients presenting with red face. Cases were collected from those attending the dermatology outpatient clinic at Minia University Hospital in the period of July 2014 to April 2017. Results: The present study was conducted on 20 patients, attending the Dermatology outpatient clinic, Minia University Hospital for treating redness of face. The age of these patients at the time of the examination ranged from 12 to 55 years. Fourteen (60%) of them were female and six (40%) were males. Summary and Conclusions: The considerable desire of patients to have healthy skin and to get rid of any dermatologic problem is matched by the number of modalities offered to patients, both medically and nonmedically, to achieve that goal. Many of these modalities have been well studied, whereas others have not. | ||||
| Keywords | ||||
| Topical; Brimonidine | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 87 PDF Download: 668 |
||||
